Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.

PURPOSE: Bevacizumab, an anti-VEGFA antibody, inhibits the developing vasculature of tumors, but resistance is common. Antiangiogenic therapy induces hypoxia and we observed increased expression of hypoxia-regulated genes, including carbonic anhydrase IX (CAIX), in response to bevacizumab treatment...

Full description

Bibliographic Details
Main Authors:	McIntyre, A, Patiar, S, Wigfield, S, Li, J, Ledaki, I, Turley, H, Leek, R, Snell, C, Gatter, K, Sly, W, Vaughan-Jones, R, Swietach, P, Harris, A
Format:	Journal article
Language:	English
Published:	2012

Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.

Similar Items